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SUMMARY. Volumetric laser endomicroscopy (VLE) uses optical coherence tomography (OCT) for real-time,
microscopic cross-sectional imaging. A US-based multi-center registry was constructed to prospectively collect
data on patients undergoing upper endoscopy during which a VLE scan was performed. The objective of this
registry was to determine usage patterns of VLE in clinical practice and to estimate quantitative and qualita-
tive performance metrics as they are applied to Barrett’s esophagus (BE) management. All procedures utilized
the NvisionVLE Imaging System (NinePoint Medical, Bedford, MA) which was used by investigators to iden-
tify the tissue types present, along with focal areas of concern. Following the VLE procedure, investigators were
asked to answer six key questions regarding how VLE impacted each case. Statistical analyses including neo-
plasia diagnostic yield improvement using VLE was performed. One thousand patients were enrolled across 18
US trial sites from August 2014 through April 2016. In patients with previously diagnosed or suspected BE
(894/1000), investigators used VLE and identified areas of concern not seen on white light endoscopy (WLE) in
59% of the procedures. VLE imaging also guided tissue acquisition and treatment in 71% and 54% of proce-
dures, respectively. VLE as an adjunct modality improved the neoplasia diagnostic yield by 55% beyond the stan-
dard of care practice. In patients with no prior history of therapy, and without visual findings from other tech-
nologies, VLE-guided tissue acquisition increased neoplasia detection over random biopsies by 700%. Registry
investigators reported that VLE improved the BE management process when used as an adjunct tissue acquisi-
tion and treatment guidance tool. The ability of VLE to image large segments of the esophagus with microscopic
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cross-sectional detail may provide additional benefits including higher yield biopsies and more efficient tissue acqui-
sition. Clinicaltrials.gov NCT02215291
KEYWORDS: Barrett’s esophagus, dysplasia, endomicroscopy, imaging.
INTRODUCTION
Barrett’s esophagus (BE) is a risk factor for the devel-
opment of esophageal adenocarcinoma (EAC).1–4
Challenges in the management of patients with BE
include detecting areas of dysplasia or superficial
cancer and surveillance after endoscopic treatment
to evaluate for residual or recurrent disease. Dys-
plasia in BE may not be apparent during inspection
using white light endoscopy (WLE). Therefore, cur-
rent guidelines recommend endoscopic surveillance of
BEwith random 4-quadrant biopsy sampling every 1–
2 cm (Seattle Protocol), in addition to targeted biopsy
sampling of any visible abnormalities.5,6 This imper-
fect surveillance protocol can result in missed disease,
with an estimated 25.3% of EACprocedures occurring
within 1 year of a surveillance endoscopy.6
Dysplasia can be treated with endoscopic thera-
pies including endoscopic mucosal resection (EMR),7
radiofrequency ablation (RFA),8 cryotherapy,9 and
others.10,11 However, high recurrence rates have been
reported, including up to 33% recurrence of intestinal
metaplasia or dysplasia at 2 years in the case ofRFA.12
Residual disease, particularly at the GEJ, and the exis-
tence of disease buried beneath neosquamous epithe-
lium are also sources of concern.13-17
Recently, advanced imaging techniques such as
narrow band imaging (NBI) and confocal laser
endomicroscopy (CLE) have sought to improve dys-
plasia detection in BE patients by allowing biop-
sies to be taken in a targeted rather than random
fashion, even when focal abnormalities are absent
on WLE inspection.18-22 Volumetric laser endomi-
croscopy (VLE) utilizes optical coherence tomog-
raphy (OCT) to produce high-resolution, cross-
sectional surface, and subsurface images of the
esophageal wall over a long continuous segment
(Fig.1).23-27 Studies have examined the efficacy of
VLE as applied to dysplasia detection in pre and post-
treatment surveillance28-30 as well as informing treat-
ment selection.29 While the safety and feasibility of
esophageal VLE imaging has been shown,31 the objec-
tive of this registry was to determine usage patterns
of VLE in clinical practice and to estimate quantita-
tive and qualitative performance metrics as they are
applied to BE management.
MATERIALS ANDMETHODS
Patient selection
This is a prospective observational cohort study from
August 2014 to April 2016. Patients were eligible
for inclusion in this study if undergoing a clinically-
indicated upper endoscopy during which VLE was
used for evaluation of the esophagus. Procedures were
performed at 18 centers throughout the United States
(Table 1). Each site was eligible to enroll up to 100 sub-
jects, with an overall registry enrollment cap of 1000
patients. Investigators were free to recruit patients
with a variety of disease states at various stages of
clinical management. Patients for whom the VLE
device would be in conflict with the manufacturer’s
Instructions For Use were excluded. This included use
in anatomies where catheter deployment would gen-
erate significant risk, such as the setting of a tight
stricture. The research protocol and informed con-
sent forms were approved by each of the participating
institutional review boards, and informed consent was
obtained from each participant prior to enrollment.
Endoscopic procedure and postprocedure questionnaire
All patients underwent standard of care endoscopy
including WLE in accordance with their institu-
tion’s standard procedures followed by VLE exami-
nation. Sample VLE features relevant to normal and
abnormal structures in the esophagus were used as
a general guideline to interpret VLE images in the
study (Fig. 2).28,31–33 Investigators were trained on the
use of the technology and supported as needed onsite
and offsite by technical experts from the sponsor
throughout the study. VLE scans were registered lon-
gitudinally and rotationally with the WLE image of
the esophagus. When a lesion was identified on VLE,
Fig. 1 NinePoint Medical, NvisionVLE Imaging System with
Single-Use Optical Probe.
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Table 1 Enrollment by Registry Site
Institution
Number
of patients
enrolled
Temple University Hospital 100
North Shore University Hospital 100
Ochsner-Kenner Medical Center 100
West Penn Allegheny Hospital 100
VA Boston Hospital 73
Dartmouth-Hitchcock Medical Center 73
Beth Israel Deaconess Medical Center 71
Geisinger Medical Center 54
Weill Cornell Medical Center 46
UC Irvine Medical Center 45
University of South Alabama Medical Center 43
Methodist Dallas Medical Center 41
Mayo Clinic Florida 35
Keck Hospital of USC 30
Florida Hospital 29
University of Vermont Medical Center 27
University of Chicago Medical Center 26
Columbia University Medical Center 7
Total 1000
Fig. 2 Sample VLE features: (A) Normal squamous epithelium,
showing well-defined layers of the esophagus. (B) Gastric cardia
identified with gastric rugae and pit-and-crypt architecture (arrow).
(C) NDBE seen with an irregular surface, isolated, round, reg-
ular, gland in the epithelium (arrow) and a partially effaced layer.
(D) dysplastic BE showing complete layer effacement with atypical
glands (arrows).
the investigator would triangulate the location of the
lesion by recording the distance and clockface reg-
istered with the WLE orientation. This information
then was used to guide the investigator to acquire the
tissue using WLE. At the time of the study, this was
the method that was available to target a tissue site for
sampling. Additional procedure details can be found
in Supplementary Material A.
Following VLE, each investigator performed any
desired diagnostic or therapeutic actions based on
their standard of care according to WLE and
advanced imaging findings. Highest grade of disease
on the pathology results was recorded for advanced
imaging guided tissue acquisition, targeted endo-
scopic tissue acquisition, and random biopsies. VLE
guided tissue acquisition refers to the subgroup of
advanced imaging guided tissue biopsy or resection
specimens where only VLE imaging was used to iden-
tify the areas of interest.
Investigators were given a questionnaire post-
procedure (Table 2) and data were collected as to
the clinical workflow and utility of the VLE images.
The questions included whether VLE guided either
their tissue sampling or therapeutic decisions for each
patient, and whether VLE identified suspicious areas
not seen on WLE or other advanced imaging modali-
ties.
Data analysis
Descriptive statistics were used for quantitative anal-
yses in the study. In light of the vast majority of
registry patients having suspected or confirmed BE,
the investigators elected to focus initial analysis on
this group and to assess potential roles of VLE in
BE management. Suspected BE refers to patients
with no prior histologic confirmation of BE who had
salmon colored mucosa found on endoscopic exami-
nation with WLE. The analysis focused on the incre-
mental diagnostic yield improvement of VLE as an
adjunct modality on top of the standard of care prac-
tice. Procedures with confirmed neoplasia (defined as
high grade dysplasia [HGD], intramucosal carcinoma
[IMC], and esophageal adenocarcinoma [EAC]) were
included in the analysis. The procedures were divided
into subgroups according to whether the tissue acqui-
sitionmethodwasVLE targeted.Dysplasia diagnostic
yields were calculated using the number of procedures
in each subgroup and total number of procedures in
patients with previously diagnosed or suspected BE.
Negative predictive value (NPV) analysis in patients
with prior BE treatment evaluated the utility of VLE
on top of the standard of care (SoC) surveillance to
predict when there is no dysplasia present. Procedures
with negative endoscopy findings and negative VLE
findings but with tissue acquisition performed were
included in the analysis and NPVs for both SoC and
SoC + VLE were calculated.
The primary evaluation focused on HGD and
cancer since the recommended image interpretation
criteria were validated for detecting BE-related neo-
plasia,28 and treatment is recommended for patients
with neoplasia per existing guidelines.34,35
RESULTS
From August 2014 through April 2016, 1000 patients
were enrolled across 18 trial sites (Table 1). The
majority of patients were male (734), with a mean age
of 64 years (range: 21–89). A total of 894 patients
had suspected or confirmed BE at the time of enroll-
ment including 103 patients with suspected BE and
791 patients with prior histological confirmation. Of
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Table 2 Post-procedure questionnaire and results
Question % Responding ‘Yes’
1 Suspicious areas/disease identified on VLE by the physician? 77% (689/894)
2 Did you see any suspicious areas on VLE that you did NOT see on WLE? 59% (526/894)
3 Did you see any suspicious areas on VLE that you did NOT see using advanced imaging (i.e. NBI,
FICE, i-Scan, chromatography, or CLE)?
56% (401/710)
4 Did VLE guide tissue acquisition? 72% (515/714)
5 Did findings on VLE guide treatment at the current visit? 52% (182/352)
6 Was either the depth or extent of disease identified on VLE used to determine treatment modality? 40% (140/353)
CLE, confocal laser endomicroscopy; NBI, narrow band imaging; VLE, volumetric laser endomicroscopy; WLE, white light endoscopy.
Table 3 Demographics and patient history
Overall
Previously
diagnosed or
suspected BE
Number of patients 1000 patients 894 patients
Median age (range) 64 years (21–89) 65 years (22–89)
Male (%) 734 (73%) 679 (76%)
Prior highest grade of pathology 845 patients 791 patients
Invasive Adenocarcinoma 34 (4.1%) 30 (3.8%)
BE with IMC 82 (10%) 82 (10.4%)
BE with HGD 258 (31%) 256 (32.3%)
BE with LGD 170 (20%) 170 (21.5%)
BE with IND 50 (6%) 49 (6.2%)
NDBE 204 (24%) 204 (25.8%)
Squamous dysplasia 20 (2%) N/A
Other 27 (3%) N/A
Prior treatment† 549 patients 501 patients
RFA 381 (69.4%) 369 (73.6%)
Cryo 90 (16.4%) 85 (17%)
EMR 197 (35.9%) 192 (38.3%)
Other 67 (12.2%) 41 (8.2%)
†Some patients had more than one esophageal intervention.
BE, Barrett’s esophagus; IMC, intramucosal carcinoma; HGD, high grade dysplasia;
LGD, low grade dysplasia; IND, indefinite for dysplasia; NDBE, non-dysplastic BE;RFA,
radiofrequency ablation; Cryo, Cryoablation; EMR, Endoscopic Mucosal Resection.
the confirmedBEpatients, 368 hadBEwith neoplasia,
170 had BE with low grade dysplasia (LGD), 49 had
BE indefinite for dysplasia (IND), and 204 had non-
dysplastic BE (NDBE). A total of 56% of patients had
undergone prior endoscopic or surgical interventions
for BE including RFA, Cryo, and EMR (Table 3).
Post-procedure questionnaires were completed for
all procedures in patients with previously diagnosed
or suspected BE (Table 2). VLE identified focal
areas of concern in 77% of BE procedures. In over
half of the procedures, investigators identified areas of
concern not seen on either WLE or other advanced
imaging modalities. Both VLE and endoscopic BE
treatment were performed in 352 procedures. VLE
guided the intervention in 52% of these procedures.
In 40% of procedures, the depth or extent of disease
identified on VLE aided the selection of a treatment
modality.
Neoplasia (43 HGD, 12 IMC, and 21 EAC) was
confirmed on tissue sampling performed in 76 pro-
cedures within the cohort of patients with previously
diagnosed or suspected BE (Fig. 3). Among these pro-
cedures, VLE-guided tissue acquisition alone found
neoplasia in 26 procedures (34%), with an additional
case where HGD on random forceps biopsy was
upstaged to IMC on VLE-targeted sampling. His-
tology from these procedures included 16 HGD, 5
IMC, and 6 EAC. Thus, VLE-guided tissue acquisi-
tion as an adjunct to standard practice detected neo-
plasia in an additional 3% (26/894) of the entire cohort
of patients with previously diagnosed or suspected
BE, and improved the diagnostic yield by at least 55%
(27 patients with neoplasia found on VLE/49 patients
with neoplasia found on standard of care imaging)
(Fig. 3).
Of the 894 BE patients, 393 (44%) had no prior his-
tory of esophageal therapy. Mean Prague classifica-
tion score for this cohort were C = 2.3 cm (range:
0–17 cm), M = 4.1 cm (range: 0.5–18 cm). In 199
(51%) of these treatment naı¨ve patients, VLE identi-
fied at least one focally suspicious area not appreci-
ated during either WLE or other advanced imaging
evaluation. Neoplasia was confirmed on histology in
24 procedures (Fig. 3). In (20/24) of these procedures,
VLE alone identified neoplasia as all random biopsies
for these patients were negative. Additionally, one case
VLE Registry 5
Fig. 3 Flow chart describing the diagnostic yield improvement analysis. ADV, advanced imagingmodality other thanVLE;ADV-: no lesion
or suspicious area was identified using advanced imaging other than VLE; RBx: random biopsy; VLE, volumetric laser endomicroscopy;
WLE, white light endoscopy.
Table 4 Pathology in treatment-naı¨ve patients with neoplasia
when positive VLE but negative WLE or other advanced imaging
findings
Pathology
Random
biopsies only
VLE-guided
only Total
EAC 0 3 3
IMC 0 5 5
HGD 3 13 16
Note: There were no cases where both random and VLE-guided
biopsies found neoplasia in the same patient.
EAC, esophageal adenocarcinoma; HGD, high grade dys-
plasia; IMC, intramucosal carcinoma; VLE, volumetric laser
endomicroscopy.
where HGDwas found on random forceps biopsy was
upstaged to IMC on VLE-targeted sampling. In this
group, VLE-guided tissue acquisition increased neo-
plasia detection by 700% (21/3) (Table 4).
For these untreated BE patients, VLE-guided
tissue acquisition as an adjunct to standard practice
detected neoplasia in an additional 5.3% of proce-
dures (21/393). The number needed to test with VLE
to identify neoplasia not detected with standard of
care technique was 18.7. An average of 1.7 additional
sites per patient required targeted tissue acquisition
when suspected regions were identified using VLE
compared to an average of 11 random biopsies per
patient.
A sub-analysis was conducted in the 238 patients
with prior BE treatment and either no visible BE
(C0M0) or irregular z-line. From this group, 82%
(211/238) had no focally suspicious findings on
WLE examination, where two procedures were sub-
sequently diagnosed with neoplasia (1 HGD and 1
EAC). Thus, the NPV for WLE was 99% (209/211,
CI = [96.2%, 99.8%]) for neoplasia. When combining
WLE/NBI with VLE as an adjunct, we found that
49% (103/211) of the post-treatment procedures had
no suspicious WLE or VLE findings. Neoplasia was
found in none of these procedures, corresponding to a
negative predictive value of 100% (CI = [95.5%,
100%]) (Fig. 4).
DISCUSSION
Advanced imaging techniques including high
definition-WLE, NBI, CLE, and chromoendoscopy
have continued to improve the evaluation of Barrett’s
esophagus. However, these provide only superficial
epithelial evaluation. VLE breaks this boundary by
imaging the mucosa, submucosa, and frequently,
down to the muscularis propria. It does so while
evaluating a large tissue area in a short period of time
without sacrificing resolution.
This 1000-patient multi-center registry assessed
the clinical utility of VLE for the management of
esophageal disorders and has demonstrated its poten-
tial as an adjunct tool for detecting disease. Abnor-
malities were found on VLE which were not seen
with other imaging in over half of the procedures.
Endoscopists using VLE in this study felt that it
guided tissue acquisition in over 70% of procedures
and BE treatment in the majority of procedures
where interventions were performed. VLE visualiza-
tion of subsurface tissue structures allows comprehen-
sive morphological evaluation, resulting in physicians
reporting suspicious areas only seen on VLE when
other advanced imaging modalities were also used in
more than half of procedures. Although subjective,
these results still provide useful insight into the physi-
cians’ perception of the technology.
This study found that VLE as an adjunct modality
increased neoplasia diagnosis by 3%, and improved
the neoplasia diagnostic yield by 55% over standard
practice and other advanced imagingmodalities. For a
treatment naı¨ve population with no focally suspicious
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Fig. 4 Flow chart describing the negative predictive value analysis. EAC, esophageal adenocarcinoma; HGD, high grade dysplasia; IMC,
intramucosal carcinoma; VLE, volumetric laser endomicroscopy; WLE, white light endoscopy.
regions found on WLE, VLE-guided tissue acquisi-
tion improved neoplastic diagnostic yield by 700%.
This finding is impressive, particularly as these pro-
cedures were performed prior to the release of a real-
time laser marking system.30 Laser marking has since
been evaluated by Alshelleh et al., who found a sta-
tistically significant improvement of neoplasia (14%
vs. 1%, P = 0.001) yield using the VLE laser marking
system compared to the standard Seattle protocol.36
In this registry, an additional 2.3 sites per patient
on average required guided biopsy or resection when
suspected regions were identified using VLE, while
an average of 15.8 random biopsies per patient
were performed in the cohort of patients with pre-
viously diagnosed or suspected BE (894/1000). In
general, higher tissue sampling density leads to an
increased chance of detecting dysplasia due to its
focal nature, therefore taking additional biopsies
should increase the diagnostic yield. However, the
potential for advanced imaging such as VLE to
provide targeted, high yield biopsies could reduce
the total number of biopsies necessary to ade-
quately evaluate the diseased mucosa with the Seattle
protocol.
The combination of a focally unremarkable WLE
and VLE examination provided a negative predictive
value of 100% for neoplasia in post-treatment popu-
lation. Although not reaching statistical significance
due to limited sample size, these early results provide
promise for the utility of VLE to better predict when
there is no disease present, i.e. a ‘clean scan.’ Such a
tool could then potentially allow for extended surveil-
lance intervals reducing the number of endoscopies to
manage the patient’s needs.
The utility of this analysis is subject to several lim-
itations. As a post-market registry study, there was
no defined protocol for imaging, image interpretation
and tissue acquisition, and there was no control group
for matched population comparisons. The early expe-
rience of users on VLE image interpretation may have
resulted in overcalling areas of concern. Abnormali-
ties located deeper in the esophageal wall could be tar-
geted with forceps biopsies at one site, while other sites
would utilize endoscopic resection techniques that are
more likely to remove the target. All of these dis-
crepancies could affect any calculations regarding the
adjunctive yield of VLE-targeted sampling. Further
analysis of the global detection rate of dysplasia by
site did not reveal any statistical difference.
At the time of this study, image interpretation was
performed using previously published guidelines for
detection of neoplasia in Barrett’s esophagus with
OCT.28 Challenges with histopathological diagnosis
of LGD limited the development of VLE criteria for
LGD. As such, the analyses in this study focused on
neoplasia. Current guidelines suggest that treatment
of LGD is acceptable35 so detection of LGDwithVLE
should be addressed in a future study.
Additionally, the characteristic image features that
maximize sensitivity and specificity of confirmatory
biopsies must be optimized. Recently, Leggett et al.
established an updated step-wise diagnostic algo-
rithm to detect dysplasia based on similar VLE
features used in this study.32 This diagnostic algo-
rithm achieved 86% sensitivity, 88% specificity, and
87% diagnostic accuracy to detect BE dysplasia with
almost perfect interobserver agreement among three
raters (kappa = 0.86).32 Further optimization of VLE
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image features for identifying dysplasia and neoplasia
are ongoing (Clinicaltrials.gov NCT02864043).
Other limitations of the study include the lack
of central pathology for interpretation of speci-
mens, which could affect (positively or negatively)
the reported benefit of VLE in finding dysplasia.
However, this manuscript focuses on neoplasia where
there is less interobserver variability compared to low-
grade dysplasia. Finally, as a non-randomized study
conducted mostly at large BE referral centers with
possibly higher pre-test probability of neoplasias, it
is plausible that their validity in a community set-
ting is limited. However, the large sample size, its het-
erogeneity, plus variation in technique by site likely
restore at least some of the external validity of the find-
ings.
This registry-based study demonstrates the poten-
tial for VLE to fill clinically relevant gaps in our ability
to evaluate and manage BE. Physicians perceived sig-
nificant value of VLE across the BE surveillance and
treatment paradigm. Biopsy confirmation demon-
strated benefits of VLE for both treatment naı¨ve
and posttreatment surveillance, although pathology
results did not always align with physician perception,
most likely due to limitations of the technology and
image criteria at the time of study. Given expected
refinement and validation of image interpretation, and
the availability of laser-marking for more accurate
biopsy targeting, VLE is well positioned to enhance
our ability to identify and target advanced disease and
enable a more efficient endoscopic examination with
higher yield of tissue acquisition.
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